[ad_1]
NEW YORK, January 22, 2019 / PRNewswire / –
About this market
Development of gene therapy to stimulate market growth. The progress of regenerative drugs in clinical phases is expected to fuel the growth of the global market for hemoglobinopathies. Technavio badysts predicted that the market for hemoglobinopathies would have a CAGR of almost 11% by 2023.
Read the full report: https://www.reportlinker.com/p05724821
Market overview
Strong pipeline and expected approvals of the molecule in the final phase
The market is facing a serious shortage of approved therapies. These molecules in the final phase of development are expected to grow during the forecast period, which will fuel market growth.
Product Recalls and Tedious Drug Approval Process
Strict regulation of marketing approval of drugs under development for the treatment of hemoglobinopathies may pose a threat to the market.
See our report for a detailed list of factors that will guide and challenge the growth of the hemoglobinopathies market over the 2019-2023 period.
Competitive landscape
The market seems to be fragmented and with the presence of several companies including Medunik United States and Novartis, the competition is very intense. Factors such as the strong potential for development and the expected approval of the end-stage molecule and the development of gene therapy will provide significant growth opportunities for manufacturers of hemoglobinopathy. ApoPharma, Bristol-Myers Squibb, Emmaus Medical, Medunik United Statesand Novartis are some of the key companies covered by this report.
Read the full report: https://www.reportlinker.com/p05724821
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker researches and organizes the industry's most up-to-date data so you have all the market research you need – instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339) 368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
http://www.reportlinker.com
Source link
